Edition:
United States

Edwards Lifesciences Corp (EW)

EW on New York Consolidated

135.64USD
23 Feb 2018
Change (% chg)

$1.97 (+1.47%)
Prev Close
$133.67
Open
$134.11
Day's High
$135.69
Day's Low
$133.01
Volume
865,356
Avg. Vol
1,511,276
52-wk High
$138.48
52-wk Low
$89.20

Latest Key Developments (Source: Significant Developments)

Edwards Says Its Self-Expanding Transcatheter Heart Valve Receives CE Mark
Thursday, 15 Feb 2018 08:00am EST 

Feb 15 (Reuters) - Edwards Lifesciences Corp ::GOT CE MARK FOR SELF-EXPANDING CENTERA VALVE FOR SEVERE, SYMPTOMATIC AORTIC STENOSIS PATIENTS AT HIGH RISK OF OPEN-HEART SURGERY.CENTERA VALVE IS NOT APPROVED FOR COMMERCIAL SALE IN U.S..  Full Article

Edwards Lifesciences Reports Qtrly Adj EPS of $0.94
Thursday, 1 Feb 2018 04:15pm EST 

Feb 1 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES QTRLY EARNINGS PER SHARE $0.17; QTRLY ADJUSTED EARNINGS PER SHARE $0.94.EDWARDS LIFESCIENCES QTRLY TRANSCATHETER HEART VALVE THERAPY SALES $519.3 MILLION, UP 20.2 PERCENT.EDWARDS LIFESCIENCES QTRLY NET SALES $888.5 MILLION, UP 15.7 PERCENT; QTRLY ADJUSTED SALES $909.4 MILLION, UP 15.9 PERCENT.EDWARDS LIFESCIENCES - U.S. TAX REFORM LED TO NET $223.5 MILLION TAX EXPENSE RELATED PRIMARILY TO DEEMED REPATRIATION OF UNREMITTED FOREIGN EARNINGS.EDWARDS LIFESCIENCES SEES Q1 TOTAL SALES $900 MILLION - $950 MILLION; SEES Q1 ADJUSTED EARNINGS PER SHARE $1.04 - $1.14.EDWARDS LIFESCIENCES SEES 2018 ADJUSTED EARNINGS PER SHARE $4.43 - $4.63.EDWARDS LIFESCIENCES SEES 2018 SALES TO BE AT HIGHER END OF $3.5 BILLION TO $3.9 BILLION RANGE.Q4 EARNINGS PER SHARE VIEW $0.91, REVENUE VIEW $867.1 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.26, REVENUE VIEW $3.74 BILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $1.03, REVENUE VIEW $901.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Edwards Lifesciences Corp Acquires Harpoon Medical
Wednesday, 6 Dec 2017 04:30pm EST 

Dec 6 (Reuters) - Edwards Lifesciences Corp ::EDWARDS ACQUIRES HARPOON MEDICAL.EDWARDS LIFESCIENCES CORP - EDWARDS PAID $100 MILLION IN CASH FOR HARPOON AT CLOSING ON DEC. 1.EDWARDS LIFESCIENCES - THERE IS POTENTIAL FOR UP TO $150 MILLION IN MILESTONE PAYMENTS OVER NEXT 10 YEARS AS PART OF DEAL.EDWARDS LIFESCIENCES - JAMES GAMMIE HAD AN EQUITY INTEREST IN HARPOON MEDICAL, AND WILL SERVE AS A CONSULTANT TO EDWARDS LIFESCIENCES.  Full Article

Edwards Lifesciences reports quarterly share of $0.79
Tuesday, 24 Oct 2017 04:15pm EDT 

Oct 24 (Reuters) - Edwards Lifesciences Corp ::Edwards Lifesciences - Qtrly earnings per share $0.79; Qtrly adjusted earnings per share $0.84; Qtrly sales $821.5 million, up 11.1 percent.Edwards Lifesciences - Qtrly Transcatheter Heart Valve Therapy sales of $481.2 million, up 17.3 percent.Q3 earnings per share view $0.86, revenue view $832.0 million -- Thomson Reuters I/B/E/S.Edwards lifesciences - Reaffirmed FY sales estimate at high end of $3.2 to $3.4 billion range, FY adjusted EPS estimate of $3.65 to $3.85.Edwards lifesciences - "Experienced minimal business impact" from recent natural disasters.FY2017 earnings per share view $3.78, revenue view $3.39 billion -- Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences Q2 shr $0.86 , Q2 adj shr $1.08
Wednesday, 26 Jul 2017 04:15pm EDT 

July 26 (Reuters) - Edwards Lifesciences Corp :Edwards lifesciences says 2017 adjusted eps guidance increased to $3.65 to $3.85, from $3.43 to $3.55.Edwards lifesciences corp q2 earnings per share $0.86; q2 adjusted earnings per share $1.08; q2 sales up 11 percent to $842 million; q2 underlying sales up 15 percent to $864 million.Edwards lifesciences q2 transcatheter heart valve therapy sales $487.5 million, a 16.5 percent growth rate over q2 last year, or 23.3 percent on an underlying basis.Edwards lifesciences says for fy 2017 sales estimate is now at high end of previous $3.2 billion to $3.4 billion guidance.Edwards lifesciences says for q3 projects underlying sales, adjusting for impact of germany stocking sales consumption, to be between $810 million and $850 million.Edwards lifesciences says projects q3 adjusted eps, adjusting for impact of germany stocking sales consumption, of $0.80 to $0.90.Q2 earnings per share view $0.88, revenue view $840.1 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $3.53, revenue view $3.35 billion -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.83, revenue view $824.7 million -- Thomson Reuters I/B/E/S.Edwards lifesciences says q2 reported, adjusted eps include $0.13 favorable impact from excess tax benefit related to employee stock-based compensation.  Full Article

Edwards' Inspiris Resilia valve receives FDA approval
Wednesday, 5 Jul 2017 09:00am EDT 

July 5 (Reuters) - Edwards Lifesciences Corp :Edwards' Inspiris Resilia valve receives FDA approval.Edwards Lifesciences Corp - Received U.S. FDA approval for its Inspiris Resilia aortic valve, first in a new class of resilient heart valves.  Full Article

Neovasc says German Court partially found in favor of Edwards Lifesciences in its case against co
Friday, 16 Jun 2017 10:44am EDT 

June 16 (Reuters) - Neovasc Inc ::Neovasc announces German Court ruling.District court in Munich has partially found in favour of Edwards Lifesciences Corporation in its case against Neovasc.German Court found CardiAQ had contributed in part to invention of Tiara, awarded to CardiAQ co-entitlement rights to disputed Tiara European patent application.Neovasc intends to appeal Court's decision.There are no monetary awards associated with the Court ruling.Currently appealing 2016 decision from U.S Court which granted co-inventorship rights to Edwards on one of co's granted U.S. patent applications.Expects oral argument on appeal regarding the 2016 decision by U.S. Court in August 2017 and ruling is expected to follow, prior to end of 2017.  Full Article

Edwards Lifesciences says SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures
Monday, 5 Jun 2017 04:30pm EDT 

June 5 (Reuters) - Edwards Lifesciences Corp :Edwards SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures.  Full Article

FDA expands use of Sapien 3 artificial heart valve for high-risk patients‍​
Monday, 5 Jun 2017 03:31pm EDT 

June 5 (Reuters) - U.S. Food and Drug Administration (FDA) : :FDA expands use of Sapien 3 artificial heart valve for high-risk patients‍​.U.S. FDA says granted accelerated approval of Sapien 3 THV to Edwards Lifesciences LLC.  Full Article

Edwards Lifesciences Q1 earnings per share $1.06
Tuesday, 25 Apr 2017 04:15pm EDT 

April 25 (Reuters) - Edwards Lifesciences Corp ::Says Q1 earnings per share $1.06; Q1 adjusted earnings per share $0.94; Q1 sales grew 27 percent to $884 million.Edwards Lifesciences Corp - narrowing its FY sales guidance to $3.2 billion to $3.4 billion, from $3.0 billion to $3.4 billion.Edwards Lifesciences Corp - raising estimate for 2017 adjusted earnings per share to $3.43 to $3.55, from $3.30 to $3.45.Edwards Lifesciences - sees Q2 sales, excluding impact of germany stocking sales, between $810 million and $850 million; sees Q2 adjusted earnings per share of $0.82 to $0.92.Edwards Lifesciences Corp - Q1 transcatheter heart valve therapy sales of $539.2 million, up 46.6 percent.Q1 earnings per share view $0.82, revenue view $776.4 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $3.41, revenue view $3.26 billion -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.87, revenue view $824.1 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Edwards Says Its Self-Expanding Transcatheter Heart Valve Receives CE Mark

* GOT CE MARK FOR SELF-EXPANDING CENTERA VALVE FOR SEVERE, SYMPTOMATIC AORTIC STENOSIS PATIENTS AT HIGH RISK OF OPEN-HEART SURGERY